ShangPharma Corporation, the second-largest Chinese pharmaceutical/biotechnology R&D outsourcing firm, will see its quiet period end on Saturday, November 27. On October 18, the company raised $87 million by offering 5.8 million ADSs at $15, within the range of $14.50-$16.50. Citi and J.P. Morgan acted as lead managers on the deal.
